QGEN (Qiagen NV) Debt-to-Asset : 0.31 (As of Sep. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Qiagen NV Debt-to-Asset?

Qiagen NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $555 Mil. Qiagen NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1,365 Mil. Qiagen NV's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2024 was $6,270 Mil. Qiagen NV's debt to asset for the quarter that ended in Sep. 2024 was 0.31.

Qiagen NV Debt-to-Asset Historical Data

The historical data trend for Qiagen NV's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Debt-to-Asset Chart

Qiagen NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.33

0.32

0.30

0.25

Qiagen NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Asset	Get a 7-Day Free Trial															0.25	0.25	0.26	0.25	0.31

Competitive Comparison of Qiagen NV's Debt-to-Asset

For the Diagnostics & Research subindustry, Qiagen NV's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qiagen NV's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Qiagen NV's Debt-to-Asset falls into.

Qiagen NV Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Qiagen NV's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(610.238	+	921.824)	/	6115.19
	=	0.25

Qiagen NV's Debt-to-Asset for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(555.257	+	1364.584)	/	6270.197
	=	0.31

Qiagen NV (NYSE:QGEN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Qiagen NV Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Qiagen NV's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Qiagen NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » Debt-to-Asset

Comparable Companies

EXAS CRL MEDP RDNT RVTY GH SHC NEOG VCYT TWST TMO DHR XSWX:LONN A IQV IDXX MTD ILMN WAT NTRA

Traded in Other Exchanges

1QGEN:Italy QIAd:UK 0RLT:UK QIA:Germany QIA:Germany QIA:Germany QGE2:Austria

Address

Hulsterweg 82, Venlo, LI, NLD, 5912 PL

Website

https://www.qiagen.com

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Executives